TABLE 2

Patient Characteristics

CharacteristicSame site/scanner (n = 10)Same institution, different scanner (n = 2)Different site/scanner (n = 11)All patients (n = 23)
Age (y)53.5 (32–67)58 (45–71)66 (43–76)60 (32–76)
Body mass index at scan 1 (kg/m2)28.3 (18.3–37.6)38.6 (31.4–45.7)28.4 (22.5–43.2)28.4 (18.3–45.7)
Time between scans (d)8 (2–15)7 (1–13)10 (7–14)9 (1–15)
Lesions* (n)5 (1–9)17 (9–25)5 (1–17)5 (1–25)
Sex (n)
 Male33 (13%)
 Female102820 (87%)
Diagnosis (n)
 Breast cancer102618 (78%)
 Other55 (22%)
Ongoing treatment between scans (n)
 None257 (30%)
 Bisphosphonates or biologic only1113 (13%)
 Endocrine therapy437 (30%)
 Chemotherapy§3126 (26%)
PET/CT scanner (n)
 Discovery STE (both)10212 (52%)
 Ingenuity TF66 (26%)
 Biograph 633 (13%)
 Biograph 20 mCT22 (9%)
  • * All identified, but ≤25 lesions/patient used in analysis.

  • 1 each: colorectal, head/neck, stage IV lung, stage III melanoma, neuroendocrine/Merkel cell cancer.

  • 2 also bisphosphonates; 3 also biologic.

  • § 4 also biologic; 1 also endocrine. Biologics: erlotinib, trastuzumab, everolimus, pertuzumab, denosumab, ado-trastuzumab emtansine. Cytotoxic agents: capecitabine, cyclophosphamide, doxorubicin.

  • Continuous data are expressed as median and range.